Kong, Y., Zhao, X., Xu, M., Pan, J., Ma, Y., Zou, L., . . . Zhang, L. (2022). PD-1 Inhibitor Combined With Radiotherapy and GM-CSF (PRaG) in Patients With Metastatic Solid Tumors: An Open-Label Phase II Study. Frontiers in immunology, 13, 952066. https://doi.org/10.3389/fimmu.2022.952066
Citace podle Chicago (17th ed.)Kong, Yuehong, et al. "PD-1 Inhibitor Combined With Radiotherapy and GM-CSF (PRaG) in Patients With Metastatic Solid Tumors: An Open-Label Phase II Study." Frontiers in Immunology 13 (2022): 952066. https://doi.org/10.3389/fimmu.2022.952066.
Citace podle MLA (9th ed.)Kong, Yuehong, et al. "PD-1 Inhibitor Combined With Radiotherapy and GM-CSF (PRaG) in Patients With Metastatic Solid Tumors: An Open-Label Phase II Study." Frontiers in Immunology, vol. 13, 2022, p. 952066, https://doi.org/10.3389/fimmu.2022.952066.